Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $183

Benzinga Newsdesk www.benzinga.com Negative 54.1%

Neg 54.1% Neu 0% Pos 0%

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $186 to $183.